RBC Capital: 'What's Regeneron Pharma's (REGN) Best Next Move'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- Houthi strike on Saudi airport kills 12, worst attack on kingdom in a decade
- US consumer sentiment near record low as frustration over economy mounts
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)
June 4, 2025 5:09 AM EDTRBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $662.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Our view: In parallel with our report on potential next steps for REGN following the itepekimab setback, we conducted a flash... More



